Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban 15 mg in very elderly NVAF patients ineligible for standard oral anticoagulation
jRCT2080223211Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Edoxaban 15 mg with Placebo (2 arms). Started May 2016; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2080223211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223211.